Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botox vs Splints vs Traditional Management of Bruxism in Implant Overdenture Patients
NCT07361900Phase 1Completed
- Sponsor
- Delta University for Science and Technology
- Start
- Mar 2024
- Primary completion
- Jul 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of botulinum toxin type A in sleep bruxism (3 arms), sponsored by Delta University for Science and Technology. Primary endpoint: Overdenture Retention at 12 months. Started Mar 2024; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
sleep bruxism
Beyond the preview
Go deeper on NCT07361900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07361900.